What are the different trends in Diabetic Retinopathy Market to boost its growth? Bayer Pharmaceuticals, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, Genentech

The overall Diabetic Retinopathy Market is slated to depict a valuation of $12 billion by 2025, having registered a remuneration of $8 billion in 2018. With diabetes on an impending rise across the globe, essentially on account of the growing geriatric populace, diabetic retinopathy market has lately been gaining heavy momentum. Subject to an unhealthy lifestyle and genetic composition, the prevalence of the disease has been robustly increasing by the day, enabling the requirement of effective treatment solutions, further providing a boost to diabetic retinopathy industry. According to WHO, diabetes has taken the shape of a global epidemic which is the root cause of various diseases that can endanger human lives if left untreated.
Speaking along similar lines, diabetic retinopathy is a kind of visual disorder induced by diabetes or high blood sugar levels that block small blood vessels supplying blood to the retina. The chances of suffering from diabetic retinopathy further increase through undiagnosed diabetes and unchecked levels of blood sugar, cholesterol and blood pressure. As a sedentary lifestyle coupled with rising obesity and non-compliance to maintaining a healthy lifestyle post diagnosis is becoming pandemic, diabetic retinopathy industry is predicted to witness an appreciable CAGR between 2019-2025.
Diabetic Retinopathy Market Size was valued at USD 8 billion in 2018 and is expected to witness 6.9% CAGR from 2019 to 2025.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/486

The National Center for Biotechnology Information (NCBI) estimated that in 2010, 126.6 million people were globally affected by diabetic retinopathy - a figure that is projected to increase to 191 million in 2030. Such an increase in the incidence of this disorder will quite inevitably stimulate the diabetic retinopathy market share, as awareness about the condition is likely to increase the scope of prevention and treatment of this disease. In countries where awareness and treatment facilities are on the lower side, diabetes will continue to prevail, nonetheless, propelling the growth of diabetic retinopathy industry.

It is pivotal to remember if left untreated for long, diabetic retinopathy can evolve to become visual threatening diabetic retinopathy (VTDR), which has been identified by the NCBI to be one of the leading causes of blindness around the world. Studies by NCBI attributed 37.3 million cases of blindness due to VTDR, which may increase to 56.3 million in 2030. However, it is prudent to note that an unhealthy lifestyle is not the only cause of this disorder - the patient's advancing age plays a major role as well to cause diabetic retinopathy or age related macular degeneration (AMD). Thus, diabetic retinopathy market will continue to depict an upward trend between 2019 and 2025 not only because of the increasing cases of diabetes and AMD but also because of rising awareness about diabetic retinopathy and its blindness-causing abilities.
Non-proliferative diabetic retinopathy market is registered to have been a lucrative vertical in 2018, a trend that is predicted to continue over 2019-2025. Indeed, non-proliferative diabetic retinopathy industry size was pegged at USD 5.6 billion in 2018, pertaining to the fact that this type of disorder has better chances of being cured than proliferated diabetic retinopathy, which for the record, is a severe stage of the disorder that can lead to blindness. On that note, it is important to mention that the rising awareness about the disease has indeed prompted diabetic patients to opt for regular eye screenings, which has decreased the incidence of proliferated diabetic retinopathy, negatively impacting diabetic retinopathy industry size.

Players in the Diabetic Retinopathy market include Bayer Pharmaceuticals, Novartis AG, Regeneron Pharmaceuticals Inc., Allergan plc, ThromboGenics NV, Sirnaomics, Inc., Genentech, Alimera Sciences, Ampio Pharmaceuticals, BCN Peptides, Kowa Group.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/486

In case of proliferated diabetic retinopathy, a study suggests that an increased level of vascular endothelial growth factor (VEGF) detected in the fibrovascular tissues of eyes, has led to the usage of anti VEGF, that has proven to be one of the most effective management methods for proliferated diabetic retinopathy, driving the growth of the overall diabetic retinopathy market. Other treatment methods like intraocular steroid injection are also expected to positively influence diabetic retinopathy industry growth, subject to the growing popularity of non-invasive diabetic retinopathy treatment and easy availably of intraocular steroid injections in clinics. However, the results of intraocular steroid injections are less satisfactory than anti VEGF, and therefore will witness limited growth in diabetic retinopathy market.

Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Diabetic retinopathy industry 3600 synopsis, 2014 - 2025
2.1.1. Business trends
2.1.2. Type trends
2.1.3. Age group trends
2.1.4. Management trends
2.1.5. Distribution channel trends
2.1.6. Regional trends
Chapter 3. Diabetic Retinopathy Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2014 - 2025
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Increasing technological advancements in diabetic retinopathy surgical instruments in developed countries
3.3.1.2. Favorable reimbursement available for ophthalmologic surgeries in developed as well as developing economies
3.3.1.3. Rising prevalence of diabetes in Asia Pacific and other underdeveloped economies
3.3.1.4. Growing geriatric population in North America and Europe
3.3.2. Industry pitfalls & challenges
3.3.2.1. Post-surgical complications
3.4. Growth potential analysis
3.4.1. By type
3.4.2. By management
3.4.3. By age group
3.4.4. By distribution channel
3.5. Porter's analysis
3.6. Competitive landscape, 2017
3.6.1. Strategy dashboard
3.7. PESTEL analysis

Diabetes, once deemed as the disease that affected only the affluent, has now reached an epidemic frontier in both developed and developing countries. With the spread of diabetes, related diseases like diabetic retinopathy are also becoming rampant, on the grounds of which diabetic retinopathy industry has been progressing significantly across the globe. Say for example, Europe diabetic retinopathy market size was pegged at USD 2.3 billion in 2018, on account of the extensive awareness of the disorder as well as the availability of technologically advanced treatment options.

Innovation in medical technologies to combat this dreaded disease is expected positively impact diabetic retinopathy market. With a major upsurge in the prevalence of diabetes and growing elderly population susceptible to lifestyle diseases, it is expected that dynamic research and development in the field of diabetic retinopathy will be reinvigorated, thereby stimulating diabetic retinopathy market size in the ensuing years.

Related Reports@
Antidiabetics Market: https://www.globenewswire.com/news-release/2019/03/14/1752945/0/en/Breast-Cancer-Therapeutics-Market-to-hit-30-637-7-million-by-2025-Global-Market-Insights-Inc.html

Diabetic Foot Ulcers and Pressure Ulcers Market: https://www.marketwatch.com/press-release/global-diabetic-foot-ulcers-and-pressure-ulcers-market-size-2019-insights-and-forecast-research-report-2025-2019-11-01

The data in this Diabetic Retinopathy market research is collated via multiple channels including but not limited to primary and secondary sources, databases, business specific references and others. The study aims to offer not only commercial data but also includes analysis of important factors, technical as well as market-oriented insights.

Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Email: sales@gminsights.com

About Global Market Insights:
Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

This release was published on openPR.